Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’

ABSTRACT: This article, co-authored by a patient living with type 2 diabetes and a diabetes specialist physician, discusses the patient's experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat t...

Descripción completa

Detalles Bibliográficos
Autor principal: Evans, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167278/
https://www.ncbi.nlm.nih.gov/pubmed/30191537
http://dx.doi.org/10.1007/s13300-018-0494-1
_version_ 1783360160436060160
author Evans, Marc
author_facet Evans, Marc
collection PubMed
description ABSTRACT: This article, co-authored by a patient living with type 2 diabetes and a diabetes specialist physician, discusses the patient's experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease. The physician discusses the therapeutic challenges of SGLT2 inhibitors and the importance of education. FUNDING: Napp Pharmaceuticals, Ltd.
format Online
Article
Text
id pubmed-6167278
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-61672782018-10-08 Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’ Evans, Marc Diabetes Ther Commentary ABSTRACT: This article, co-authored by a patient living with type 2 diabetes and a diabetes specialist physician, discusses the patient's experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease. The physician discusses the therapeutic challenges of SGLT2 inhibitors and the importance of education. FUNDING: Napp Pharmaceuticals, Ltd. Springer Healthcare 2018-09-06 2018-10 /pmc/articles/PMC6167278/ /pubmed/30191537 http://dx.doi.org/10.1007/s13300-018-0494-1 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Evans, Marc
Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title_full Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title_fullStr Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title_full_unstemmed Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title_short Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
title_sort living with type 2 diabetes: patient commentary in response to the paper ‘sglt2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice’
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167278/
https://www.ncbi.nlm.nih.gov/pubmed/30191537
http://dx.doi.org/10.1007/s13300-018-0494-1
work_keys_str_mv AT livingwithtype2diabetespatientcommentaryinresponsetothepapersglt2inhibitorsintype2diabetesmanagementkeyevidenceandimplicationsforclinicalpractice
AT evansmarc livingwithtype2diabetespatientcommentaryinresponsetothepapersglt2inhibitorsintype2diabetesmanagementkeyevidenceandimplicationsforclinicalpractice

Ejemplares similares